Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Absci Corp (NQ: ABSI )

3.920 +0.080 (+2.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Absci Corp

< Previous 1 2 3 4 5 6 7 Next >
AI-Focused Drug Discovery Stocks Index Up 26% In December
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions. 
Via Talk Markets
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
From Absci Corporation
Via GlobeNewswire
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth... 
Via Benzinga
The 10 Stocks Using AI To Develop New Drugs Were Up 4%, On Average, Last Week
If, as Morgan Stanley postulates, a $50 billion AI drug discovery revolution is underway, here are 10 publicly-traded micro- and small-cap clinical stage pharma companies that are embracing AI to... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
Collaboration Combines Absci’s AI Antibody Drug Creation Platform with AstraZeneca’s Expertise in Oncology Research and Development 
From Absci Corporation
Via GlobeNewswire
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial intelligence... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Why INVO Bioscience Shares Are Trading Higher By Over 31%; Here Are 20 Stocks Moving Premarket
INVO Bioscience, Inc. (NASDAQ: INVO) shares surged in pre-market trading after the company posted a narrower loss for the third quarter. 
Via Benzinga
Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Beyond Air, Inc. (NASDAQ: XAIR) dipped during Tuesday’s session following weak quarterly results. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off Tuesday with a breakdown of all the biggest pre-market stock movers traders need to know about this morning! 
Via InvestorPlace
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
From Almirall S.A.
Via Business Wire
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases 
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen
From Absci Corporation
Via GlobeNewswire
Absci to Host R&D Day on October 4, 2023
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
The 3 Most Undervalued Penny Stocks to Buy Now: August 2023
These undervalued penny stocks each provide big upside potential, while trading with relatively high margins of safety. 
Via InvestorPlace
Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Absci Appoints Zach Jonasson, Ph.D., as Chief Financial Officer and Chief Business Officer
Addition of veteran biotech leader to further support Absci’s next stage of growth 
From Absci Corporation
Via GlobeNewswire
Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the UBS MedTech, Tools and Genomics Summit 2023
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI Summit
From Absci Corporation
Via GlobeNewswire
Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips
From Absci Corporation
Via GlobeNewswire
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share. 
Via Benzinga
Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
University of Oxford’s Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies
Absci will apply its generative AI platform to The Kennedy Institute’s immunology biorepository to speed the discovery and development of multiple therapies 
From Absci Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.